Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
It's not the severity — it's the staying power. A qualitative substudy of the phase 3 RAMPART trial found that patients with resected renal cell carcinoma (RCC) on adjuvant checkpoint inhibitors cared more about how long their side effects lasted than how intense they were. Persistent fatigue, diarrhea, and joint pain disrupted daily life, work, and mental health — with some patients reporting severe depression and suicidal thoughts.
It's not the severity — it's the staying power. A qualitative substudy of the phase 3 RAMPART trial found that patients with resected renal cell carcinoma (RCC) receiving adjuvant durvalumab (with or without tremelimumab) placed far greater weight on how long their immune-related side effects lasted than on how severe they were. Chronic fatigue — described by patients as "bone deep" and unpredictable — topped the list of burdensome symptoms, followed by diarrhea and joint pain.
The findings, published in PLOS One, also revealed a significant mental health toll. Adrenal insufficiency, which requires lifelong steroid replacement, was linked to anxiety and low mood, and some patients with persistent symptoms reported severe depression and suicidal thoughts. Socioeconomic factors played a major role too: patients in physically demanding jobs, single-income households, or caregiving roles felt the burden most acutely, while retirement, flexible employers, and strong family support were protective.
Key Takeaways:
Why it matters: As adjuvant immunotherapy becomes standard in RCC, understanding the lived experience of side effects — not just their clinical grade — is essential for truly informed consent, survivorship planning, and trial design.
